ARTICLE SUMMARY:
Breakthrough Devices would no longer enjoy a fast track to inpatient new technology add-on payments and outpatient pass-through payments under a new proposal from the Medicare agency. Companies would need to prove “substantial clinical improvement.”
The Medicare agency is proposing to beef up clinical evidence requirements for FDA-designated Breakthrough Devices to qualify for bonus payments.
